Literature DB >> 2081282

[Fluorine-19 nuclear magnetic resonance spectroscopy: a privileged tool for the study of the metabolism and pharmacokinetics of fluoropyrimidines].

M C Malet-Martino1, R Martino, J P Armand.   

Abstract

This review reports on the various studies using fluorine-19 nuclear magnetic resonance spectroscopy (19F NMR) to study the metabolism of antineoplastic or antifungal fluoropyrimidines. It is divided into 2 parts: the first examines ex vivo studies, ie, of biofluids or excised tissue samples from patients. In vivo studies, ie where the biotransformation of the drug is followed by non-invasively both in animals and in humans, are described in the second part. For ex vivo studies, 19F NMR can already be considered as complementary to the classical analytical methodologies used for drug metabolism studies. In vivo 19F NMR spectroscopic studies, especially in humans, are still at an early stage of development. Several improvements, both methodological (development of volume-selective localization techniques and quantification methods) and clinical (more rigorous definition of pathologies under study and administered treatments), are a prerequisite for useful clinical application.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2081282

Source DB:  PubMed          Journal:  Bull Cancer        ISSN: 0007-4551            Impact factor:   1.276


  3 in total

Review 1.  Uses and limitations of nuclear magnetic resonance (NMR) spectroscopy in clinical pharmacokinetics.

Authors:  M C Malet-Martino; R Martino
Journal:  Clin Pharmacokinet       Date:  1991-05       Impact factor: 6.447

2.  Evaluation of plasma 5-fluorouracil nucleoside levels in patients with metastatic breast cancer: relationships with toxicities.

Authors:  M Barberi-Heyob; B Weber; J L Merlin; C Dittrich; E A de Bruijn; E Luporsi; F Guillemin
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

3.  Cardiotoxicity of commercial 5-fluorouracil vials stems from the alkaline hydrolysis of this drug.

Authors:  L Lemaire; M C Malet-Martino; M de Forni; R Martino; B Lasserre
Journal:  Br J Cancer       Date:  1992-07       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.